SML Genetree has been selected as a Promising Company in the 2026 Global Small Giants 1000+ Project organized by Korea’s Ministry of SMEs and Startups.
'The Global Small Giants 1000+ Project' is a government support program designed to identify export-oriented SMEs with high growth potential and foster them into leading export companies by providing preferential access to a wide range of support programs, including export assistance, financing, and R&D support.
The 2026 program targets exporting SMEs with export records of at least USD 100,000 in 2025. Companies are classified into four stages—Promising, Growth, Small Giant, and Small Giant Plus—based on their export volume.
Through this selection, SML Genetree has further strengthened its position as a promising export company recognized for its global market expansion capabilities and growth potential. The company plans to accelerate its expansion into overseas markets by leveraging various preferential benefits, including export voucher programs, overseas marketing support, overseas certification support, export guarantees and insurance, policy financing, and R&D-linked support.
This selection is particularly meaningful as it represents external recognition of SML Genetree’s molecular diagnostic technologies and its potential for overseas market growth. Based on this achievement, the company plans to expand global partnerships, strengthen overseas certifications and distribution networks, and further enhance the competitiveness of its product portfolio.
Lee Dong-soo, CEO of SML Genetree, said “This selection is the result of recognition of our molecular diagnostic technologies and our potential to expand in the global market. By leveraging the policy support made available through this project, we will strengthen the trust of our overseas customers and partners and continue growing into a global diagnostics solutions company.”
Following its selection for the project, SML Genetree plans to reinforce its export capabilities and expand its overseas network, while further solidifying its position in the global diagnostics market through continued R&D investment and enhanced manufacturing competitiveness.
About SML Genetree
SML Genetree has been at the forefront of genomic research and diagnostic kit development based on molecular biology, a key pillar of the rapidly growing biotechnology industry. In 2018, the company commercialized the world’s first kit capable of detecting 100 types of HPV anytime and anywhere using NGS technology.
Since then, SML Genetree has continued to achieve remarkable growth by developing and commercializing more than 50 molecular diagnostic kits of leading domestic quality and successfully launching the brand 'NamuPlex.'
Website: http://genetree.co.kr
Source: NewsWire | 2026.05.18
https://www.newswire.co.kr/newsRead.php?no=1034581
SML Genetree has been selected as a Promising Company in the 2026 Global Small Giants 1000+ Project organized by Korea’s Ministry of SMEs and Startups.
'The Global Small Giants 1000+ Project' is a government support program designed to identify export-oriented SMEs with high growth potential and foster them into leading export companies by providing preferential access to a wide range of support programs, including export assistance, financing, and R&D support.
The 2026 program targets exporting SMEs with export records of at least USD 100,000 in 2025. Companies are classified into four stages—Promising, Growth, Small Giant, and Small Giant Plus—based on their export volume.
Through this selection, SML Genetree has further strengthened its position as a promising export company recognized for its global market expansion capabilities and growth potential. The company plans to accelerate its expansion into overseas markets by leveraging various preferential benefits, including export voucher programs, overseas marketing support, overseas certification support, export guarantees and insurance, policy financing, and R&D-linked support.
This selection is particularly meaningful as it represents external recognition of SML Genetree’s molecular diagnostic technologies and its potential for overseas market growth. Based on this achievement, the company plans to expand global partnerships, strengthen overseas certifications and distribution networks, and further enhance the competitiveness of its product portfolio.
Lee Dong-soo, CEO of SML Genetree, said “This selection is the result of recognition of our molecular diagnostic technologies and our potential to expand in the global market. By leveraging the policy support made available through this project, we will strengthen the trust of our overseas customers and partners and continue growing into a global diagnostics solutions company.”
Following its selection for the project, SML Genetree plans to reinforce its export capabilities and expand its overseas network, while further solidifying its position in the global diagnostics market through continued R&D investment and enhanced manufacturing competitiveness.
About SML Genetree
SML Genetree has been at the forefront of genomic research and diagnostic kit development based on molecular biology, a key pillar of the rapidly growing biotechnology industry. In 2018, the company commercialized the world’s first kit capable of detecting 100 types of HPV anytime and anywhere using NGS technology.
Since then, SML Genetree has continued to achieve remarkable growth by developing and commercializing more than 50 molecular diagnostic kits of leading domestic quality and successfully launching the brand 'NamuPlex.'
Website: http://genetree.co.kr
Source: NewsWire | 2026.05.18
https://www.newswire.co.kr/newsRead.php?no=1034581